Effect of oral paricalcitol on endothelial function and FGF-23 in peritoneal dialysis patients: a pilot study

• Conditions: CHRONIC RENAL FAILURE; MedDRA version: 14.1Level: PTClassification code 10038444Term: Renal failure chronicSystem Organ Class: 10038359 - Renal and urinary disorders; Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

• Registration Number: EUCTR2012-002744-24-IT
• Lead Sponsor: POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-10-11
• Last Update Posted: 10 February 2014

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Thirty patients older than 18 under peritoneal dialysis (all modalities) since at least 3 months with secondary Hyperparathyroidism.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

- poor medication compliance; - parathyroidectomy; lactation, pregnancy; treatment with cinacalcet.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified